HTG Molecular Diagnostics, Inc. (HTGM): Price and Financial Metrics
GET POWR RATINGS... FREE!
HTGM Stock Summary
- With a market capitalization of $12,032,737, Htg Molecular Diagnostics Inc has a greater market value than only 1.2% of US stocks.
- Revenue growth over the past 12 months for Htg Molecular Diagnostics Inc comes in at -20%, a number that bests only 7.25% of the US stocks we're tracking.
- Htg Molecular Diagnostics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -105.57%, greater than the shareholder yield of only 3.59% of stocks in our set.
- Stocks that are quantitatively similar to HTGM, based on their financial statements, market capitalization, and price volatility, are ICAD, PLAB, TRVN, BCOV, and SNES.
- HTGM's SEC filings can be seen here. And to visit Htg Molecular Diagnostics Inc's official web site, go to www.htgmolecular.com.
HTGM Valuation Summary
- In comparison to the median Healthcare stock, HTGM's EV/EBIT ratio is 110.24% lower, now standing at -3.
- Over the past 77 months, HTGM's price/sales ratio has gone down 21.4.
- Over the past 77 months, HTGM's price/sales ratio has gone down 21.4.
Below are key valuation metrics over time for HTGM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| HTGM | 2021-08-31 | 6.4 | 2.7 | -2.9 | -3.0 |
| HTGM | 2021-08-30 | 6.4 | 2.7 | -2.9 | -3.0 |
| HTGM | 2021-08-27 | 6.1 | 2.6 | -2.8 | -2.8 |
| HTGM | 2021-08-26 | 6.4 | 2.7 | -2.9 | -2.9 |
| HTGM | 2021-08-25 | 6.3 | 2.7 | -2.9 | -2.9 |
| HTGM | 2021-08-24 | 5.9 | 2.5 | -2.7 | -2.7 |
HTGM Growth Metrics
- Its year over year net income to common stockholders growth rate is now at -4.52%.
- Its 5 year cash and equivalents growth rate is now at 177.77%.
- The 4 year net income to common stockholders growth rate now stands at 21.69%.
The table below shows HTGM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 8.612758 | -16.66869 | -16.24386 |
| 2021-06-30 | 7.869446 | -16.81077 | -17.16503 |
| 2021-03-31 | 7.758536 | -16.71509 | -20.26063 |
| 2020-12-31 | 8.548864 | -16.29238 | -20.87022 |
| 2020-09-30 | 10.76582 | -16.59933 | -20.96955 |
| 2020-06-30 | 14.39351 | -16.31283 | -20.298 |
HTGM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HTGM has a Quality Grade of C, ranking ahead of 33.06% of graded US stocks.
- HTGM's asset turnover comes in at 0.216 -- ranking 65th of 75 Measuring and Control Equipment stocks.
- SMIT, BIO, and AATC are the stocks whose asset turnover ratios are most correlated with HTGM.
The table below shows HTGM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.216 | 0.523 | -0.726 |
| 2021-03-31 | 0.210 | 0.515 | -0.879 |
| 2020-12-31 | 0.223 | 0.533 | -0.795 |
| 2020-09-30 | 0.264 | 0.596 | -0.676 |
| 2020-06-30 | 0.325 | 0.559 | -0.705 |
| 2020-03-31 | 0.421 | 0.568 | -0.690 |
HTGM Price Target
For more insight on analysts targets of HTGM, see our HTGM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $12.75 | Average Broker Recommendation | 1.5 (Moderate Buy) |
HTGM Stock Price Chart Interactive Chart >
HTGM Price/Volume Stats
| Current price | $1.03 | 52-week high | $6.98 |
| Prev. close | $0.99 | 52-week low | $0.46 |
| Day low | $0.85 | Volume | 8,552,000 |
| Day high | $1.04 | Avg. volume | 1,630,335 |
| 50-day MA | $0.68 | Dividend yield | N/A |
| 200-day MA | $2.97 | Market Cap | 8.84M |
HTG Molecular Diagnostics, Inc. (HTGM) Company Bio
HTG Molecular Diagnostics, Inc. develops and markets technology platforms that facilitate the routine use of complex molecular profiling. The companys HTG Edge and HTG EdgeSeq platforms consist of instrumentation, consumables, and software analytics that are used in molecular profiling applications, including tumor profiling, biomarker development and prospectively, and molecular diagnostic testing. The company was founded in 1997 and is based in Tucson, Arizona.
Latest HTGM News From Around the Web
Below are the latest news stories about Htg Molecular Diagnostics Inc that investors may wish to consider to help them evaluate HTGM as an investment opportunity.
HTG Names Renowned RNA Expert Dr. Robert Spitale to Therapeutics Scientific Advisory BoardTUCSON, Ariz., Feb. 03, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed Robert Spitale, Ph.D., Associate Director and Associate Dean of Research in the School of Pharmacy and Pharmaceutical Services at the University of California, Irvine (UC Irvine), to the HTG Therapeutics Scientific Advisory Board. Dr. Spitale is a chemic |
HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of DirectorsBrings Significant Operational Experience in Building Therapeutic Drug Development BusinessesTUCSON, Ariz., Jan. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed biopharmaceutical industry veteran Christopher Kiritsy to its Board of Directors. Currently the Managing Member of Precision Kapital, LLC, a private investment a |
H.C. Wainwright Reiterates a Buy Rating on HTG Molecular Diagnostics (HTGM)In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on HTG Molecular Diagnostics (HTGM – Research Report), with a price target of $9.00. The company's shares closed last Monday at $4.42. According to TipRanks.com, Chen is a 5-star analyst with an average return of 24.9% and a 38.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and EyePoint Pharmaceuticals. HTG Molecular Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $8.50, an 88.1% upside from current levels. |
HTG Molecular Diagnostics Announces Certain Preliminary 2021 Unaudited Financial ResultsPreliminary full year 2021 unaudited revenue of $8.9 million Cash, cash equivalents and short-term marketable securities of $21.9 million as of December 31, 2021 TUCSON, Ariz., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced certain preliminary, unaudited financial results for the year ended December 31, 2021. Total revenue for the full year 2021 is expected to be approx |
HTG Molecular Diagnostics (NASDAQ:HTGM) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
HTGM Price Returns
| 1-mo | 86.09% |
| 3-mo | -22.56% |
| 6-mo | -81.00% |
| 1-year | -82.57% |
| 3-year | -95.60% |
| 5-year | -97.42% |
| YTD | -81.00% |
| 2021 | 13.15% |
| 2020 | -54.50% |
| 2019 | -72.37% |
| 2018 | 25.12% |
| 2017 | -9.38% |
Continue Researching HTGM
Here are a few links from around the web to help you further your research on Htg Molecular Diagnostics Inc's stock as an investment opportunity:Htg Molecular Diagnostics Inc (HTGM) Stock Price | Nasdaq
Htg Molecular Diagnostics Inc (HTGM) Stock Quote, History and News - Yahoo Finance
Htg Molecular Diagnostics Inc (HTGM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...